Jove
Visualize
Contact Us

Related Experiment Videos

Severe persistent cerebellar dysfunction complicating cytosine arabinoside therapy.

P Boesen1, J Fallingborg, E Spaun

  • 1Department of Haematology and Internal Medicine, Aalborg Hospital, Denmark.

Acta Medica Scandinavica
|January 1, 1988
PubMed
Summary

High-dose cytosine arabinoside (Ara-C) can cause persistent cerebellar dysfunction in acute myelogenous leukemia patients. This neurological damage appears linked to the cumulative dose, not peak drug levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year.

Alimentary pharmacology & therapeutics·2004
Same author

Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis.

Gut·2003
Same author

Brachioradial pruritus.

Journal of the American Academy of Dermatology·2001
Same author

Intraluminal pH of the human gastrointestinal tract.

Danish medical bulletin·1999
Same author

Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease.

Digestive diseases and sciences·1998
Same author

Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.

Alimentary pharmacology & therapeutics·1994
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Neuroscience
  • Oncology
  • Pharmacology

Background:

  • Cytosine arabinoside (Ara-C) is a chemotherapy agent used to treat acute myelogenous leukemia (AML).
  • Neurological adverse effects, including cerebellar dysfunction, have been associated with Ara-C treatment.
  • Understanding dose-dependent toxicity is crucial for optimizing cancer therapy.

Observation:

  • A case study details persistent cerebellar dysfunction in an AML patient after high-dose Ara-C.
  • Symptoms emerged at a cumulative dose of 24 g/m2 and remained unchanged six months later.
  • The patient experienced symptom exacerbation during subsequent low-dose Ara-C therapy.

Findings:

  • The observed cerebellar damage appears to be a result of the cumulative dose of Ara-C.

Related Experiment Videos

  • This adverse effect is likely independent of peak plasma drug concentrations.
  • The findings suggest a long-term neurotoxic potential of cumulative Ara-C exposure.

    • Implications:

    • This case highlights the importance of monitoring for neurotoxicity during and after Ara-C treatment for AML.
    • It suggests that cumulative dosing, rather than transient high concentrations, may be the primary driver of Ara-C-induced cerebellar dysfunction.
    • Further research into the mechanisms of Ara-C neurotoxicity and strategies for prevention or mitigation is warranted.